MedTrace Logo

Effect of Respiratory Virus Infection on EmeRgencY Admission Study (EVERY Study)

NCT05913700 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 3067

Last updated 2025-07-20

No results posted yet for this study

Summary

Study design is multicenter prospective registry study. Participants are consecutive (non-selected, a sequential registration) patients admitted from emergency rooms of participating hospitals who meet the eligibility criteria.

The primary objectives are to estimate the prevalence of and risk factors for RS and other respiratory virus infection and their effect on hospital course in patients with any respiratory symptom who admit from emergency room using a multicenter prospective registry study. The primary target virus is RS virus and the secondary target viruses are respiratory virus and other microorganisms measured by FilmArray 2.1.

Conditions

  • Respiratory Syncytial Virus (RSV)
  • Respiratory Viral Infection
  • Acute Disease

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Institute for Clinical Effectiveness, Japan

    lead OTHER

Principal Investigators

  • Tsukasa Nakamura, MD, PhD · Shimane Prefectural Central Hospital

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2025-01-22
Completion
2026-09-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05913700 on ClinicalTrials.gov